Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleLetters to the Editor

The Glutamate Model of Schizophrenia: It’s All About Signal Muscarinic Connections

Costa Vakalopoulos
Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 288; DOI: https://doi.org/10.1124/jpet.116.238766
Costa Vakalopoulos
Richmond Hill Medical Centre, Melbourne, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Sensorimotor gating is an endophenotype of schizophrenia that is used extensively in animal models of the disease. Memory impairments are also associated with core symptoms of schizophrenia, but defining their exact relation to explicit or implicit deficits has been more elusive (Vakalopoulos, 2011). The pervasive role of muscarinic signaling in negative and positive symptoms, endophenotypes, and memory dysfunction offers a promising area of research for a nonaminergic causal chain of events in schizophrenic pathophysiology (Vakalopoulos, 2006). NMDA receptor antagonists are useful in modeling negative symptoms. NMDA dysfunction has been proposed as a proxy for core muscarinic receptor deficits in schizophrenia, especially the deficit syndrome (Vakalopoulos, 2006, 2014). The recent study by Choy et al. (2016) demonstrates the utility of such a conceptualization in guiding translational research for more effective symptom control. The selective positive allosteric modulator (PAM) of the muscarinic m1 receptor BQCA reversed both prepulse inhibition and Y-maze spatial memory deficits in mice treated with MK-801, and this was specifically m1 receptor-dependent. Familiarity-based Y-maze performance is consistent with the modulation of implicit memory traces.

The authors speculate on the potential utility of PAMs at the muscarinic receptor in augmenting conventional antipsychotic therapy, targeting cognitive and, in particular, negative symptoms. The current suite of acetylcholine-enhancing agents has not proved clinically useful owing to a high side-effect profile. This study found that BQCA was ineffective on its own in reversing the effects of MK-801 in either paradigm. The main purpose of this letter is to explore the possible reason for this lack of effectiveness given the proposal of a primary muscarinic signaling dysfunction. If the NMDA receptor manifests critical convergent intracellular cascades, then it is likely to affect multiple muscarinic receptor subtypes. Thus, an inverse model of monoamine-muscarinic signaling (Vakalopoulos, 2006) could account for enhancement by unmasking broader muscarinic function with subthreshold doses of both atypical and typical neuroleptics. This concept is supported by the effect of the acetylcholinesterase inhibitor galantamine, but not donepezil, in reversing PPI deficits induced by MK-801 in rats (Hohnadel et al., 2007). Interestingly, another potent and highly selective PAM at m1 mitigated deficits in novel object recognition and cued fear conditioning associated with a mouse NR1 subunit of NMDA knockdown (Grannan et al., 2016). No neuroleptics were required, but 10%–15% of wild-type function is preserved in this knockdown.

In summary, research on PAMs of muscarinic receptors is certainly a game-changer in developing a new approach to therapeutics for schizophrenia and facilitating a more profound understanding of the essential nature of the disease.

Footnotes

    • Received November 3, 2016.
    • Accepted November 4, 2016.
  • dx.doi.org/10.1124/jpet.116.238766.

Abbreviations

NMDA
N-methyl-D-aspartate
PAM
positive allosteric modulator
  • Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Choy KHC,
    2. Shackleford DM,
    3. Malone DT,
    4. Mistry SN,
    5. Patil RT,
    6. Scammells PJ,
    7. Langmead CJ,
    8. Pantelis C,
    9. Sexton PM,
    10. Lane JR,
    11. et al.
    (2016) Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior. J Pharmacol Exp Ther 359:354–365.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Grannan MD,
    2. Mielnik CA,
    3. Moran SP,
    4. Gould RW,
    5. Ball J,
    6. Lu Z,
    7. Bubser M,
    8. Ramsey AJ,
    9. Abe M,
    10. Cho HP,
    11. et al.
    (2016) Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256. ACS Chem Neurosci 10.1021/acschemneuro.6b00230.
  3. ↵
    1. Hohnadel E,
    2. Bouchard K, and
    3. Terry AV Jr.
    (2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52:542–551.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Vakalopoulos C
    (2006) Neuropharmacology of cognition and memory: a unifying theory of neuromodulator imbalance in psychiatry and amnesia. Med Hypotheses 66:394–431.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Vakalopoulos C
    (2011) Implicit memory in schizophrenia: the problem that will not go away. Biol Psychiatry 69:e33 (author reply e35).
    OpenUrlPubMed
  6. ↵
    1. Vakalopoulos C
    (2014) The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis. Front Pharmacol 5:277 10.3389/fphar.2014.00277.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 360 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 360, Issue 2
1 Feb 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Glutamate Model of Schizophrenia: It’s All About Signal Muscarinic Connections
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleLetters to the Editor

Letters to the Editor

Costa Vakalopoulos
Journal of Pharmacology and Experimental Therapeutics February 1, 2017, 360 (2) 288; DOI: https://doi.org/10.1124/jpet.116.238766

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleLetters to the Editor

Letters to the Editor

Costa Vakalopoulos
Journal of Pharmacology and Experimental Therapeutics February 1, 2017, 360 (2) 288; DOI: https://doi.org/10.1124/jpet.116.238766
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • Abbreviations
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Letters to the Editor
  • Letters to the Editor
  • TDF is not an Inhibitor of OCT1
Show more LETTERS TO THE EDITOR

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics